|
Roche posts good half year results
|
23 July 2010 |
|
Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test
|
09 July 2010 |
|
RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis
|
21 June 2010 |
|
Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer
|
07 June 2010 |
|
EDUCARE (EDUcation for Cancer in African REgions) Project
|
10 May 2010 |
|
Roche Group sustained its strong sales growth in the first three months of 2010
|
28 April 2010 |
|
Roche acquires Medingo Ltd. and expands its position in the growing insulin delivery systems market
|
15 April 2010 |
|
Roche uniquely positioned to deliver long-term growth
|
22 March 2010 |
|
Roche and Biogen Idec decide to suspend Ocrelizumab treatment
|
11 March 2010 |
|
Phase III study of Avastin in advanced stomach cancer did not meet primary endpoint
|
26 February 2010 |
|
US FDA approves Rituxan/MabThera for the most common type of adult leukemia
|
23 February 2010 |
|
Roche study drug may offer valuable new treatment option for patients with type 2 diabetes
|
12 February 2010 |
|
Strong operating performance for Roche in 2009
|
05 February 2010 |
|
Roche establishes new medical research hub in Singapore
|
01 February 2010 |
|
FDA approves ACTEMRA for the treatment of moderately to severely active rheumatoid arthritis
|
13 January 2010 |
|
Herceptin provides impressive survival benefit for patients with high levels of HER2
|
25 September 2009 |
|
Analysis of BRAIN study shows that patients may have a stabilisation or improvement
|
23 September 2009 |
|
Two new studies report increased survival rates in Tamiflu-treated patients
|
15 September 2009 |
|
Roche recognised as new Super Sector Leader in Dow Jones Sustainability Index
|
04 September 2009 |
|
Avastin approved in US for the most common type of kidney cancer
|
03 August 2009 |